Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy

AMGN's 2026 guidance targets $37.0–$38.4bn in revenue and non-GAAP EPS of $21.6–$23, implying a forward P/E of ~17x. The firm is rated a Buy on robust revenue growth, recent FDA approvals and a diverse late‑stage pipeline; Tepezza's successful Phase 3 subcutaneous trial materially strengthens its position in the Thyroid Eye Disease (TED) market and supports expanded chronic use. Key downside risk is looming patent expiries on legacy drugs that could pressure future revenue.

Analysis

Tepezza’s move toward a subcutaneous, chronic-use profile is a classic product-shape shift: it converts episodic, high-touch revenue into a recurring, lower-FTE-cost stream. That favors scale players with integrated commercial footprints and long-term patient engagement capabilities; it also transfers margin pressure from infusion centers and CROs toward higher-volume CMO/device suppliers. Expect incremental demand for prefilled-device components and high-volume biologics fill/finish capacity to materialize within 6–18 months, tightening supply for suppliers that cannot ramp quickly.

Patent and lifecycle dynamics create asymmetric timing risk: near-term upside comes from label expansion and adoption curves, while downside is multi-year and concentrated around patent-litigation and biosimilar entry windows. Regulatory or payer pushback on chronic dosing could compress pricing over 12–36 months much faster than consensus models assume, creating back-loaded earnings risk even as top-line growth appears healthy today. Litigation outcomes or rapid biosimilar manufacturing scale-up are tail events that would materially erode multiples, so monitor docket timelines and CMO capacity expansions closely.

Second-order winners include device and packaging names that supply SC delivery systems; losers are localized infusion providers and commercial services that monetize IV administration. A sensible portfolio tilt is to capture optionality on adoption (long integrated commercial biotech) while hedging the longer-duration patent and pricing risk via concentrated, time-limited downside protection. The market appears to be rewarding diversification of pipeline optionality but is underweight supplier bottlenecks and real-world switching friction that can accelerate or retard adoption in measurable quarterly steps.

Key Decisions for Investors

• AMGN long-exposure with defined risk: buy AMGN 9–12 month ATM call spread (buy 1x 12mo ATM call, sell 1x 12mo ~20–30% OTM call). Rationale: capture adoption/label wins while funding premium; target 2.0–3.0x upside if adoption accelerates. Max loss = premium paid; hold through the next two quarterly uptake prints.
• Supply-chain convexity play: long West Pharmaceutical Services (WST) 6–12 month calls (or buy stock if conservative). Rationale: benefit from increased demand for prefilled-device components as SC formulations scale. Risk: execution/competitive pricing; reward: >2x if supplier capacity tightness persists for 6–18 months.
• Downside hedge to patent/cost risk: buy 18–24 month AMGN puts (or put calendar) sized at 25–40% of equity position to protect against adverse litigation/biosimilar shocks. Rationale: insures multi-year downside from rapid biosimilar entry or payer-enforced price erosion. Cost = insurance premium; preserves long-term upside.
• Pairs idea for neutral capital: long AMGN equity / short a pure-play infusion services or outpatient IV operator (size 1:0.25–0.5). Rationale: capture margin shift from infusion centers to SC self-administration. Timeframe: 6–18 months; expected asymmetric payoff if SC adoption reduces infusion volumes materially.